Colorectal cancer is the third most common cause of cancer-related deaths and the second most prevalent (after breast cancer) in the western world. High metastatic relapse rates and severe side effects associated with the adjuvant treatment have urged oncologists and clinicians to find a novel, less toxic therapeutic strategy. Considering the limited success of the past clinical trials involving peptide vaccine therapy to treat colorectal cancer, it is necessary to revise our knowledge of the immune system and its potential use in tackling cancer. This review presents the efforts of the scientific community in the development of peptide vaccine therapy for colorectal cancer. We review recent clinical trials and the strategies for immunologic monitoring of responses to peptide vaccine therapy. We also discuss the mechanisms underlying the therapy and potential molecular targets in colon cancer.
References
[1]
Ferlay, J.; Autier, P.; Boniol, M.; Heanue, M.; Colombet, M.; Boyle, P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 2007, 18, 581–592.
[2]
Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.Q.; Thun, M.J. Cancer statistics 2007. CA Cancer J. Clin. 2007, 57, 43–66, doi:10.3322/canjclin.57.1.43.
[3]
American Cancer Society (ACS). Cancer Facts and Figures 2008; ACS: Atlanta, GA, USA, 2008.
[4]
Parkin, D.M.; Bray, F.I.; Devesa, S.S. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 2001, 37, S4–S66.
[5]
Holt, P.R.; Kozuch, P.; Mewar, S. Colon cancer and the elderly: From screening to treatment in management of GI disease in the elderly. Best Pract. Res. Clin. Gastroenterol. 2009, 23, 889–907, doi:10.1016/j.bpg.2009.10.010.
[6]
Ragnhammar, P.; Hafstrom, L.; Nygren, P.; Glimelius, B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol. 2001, 40, 282–308.
[7]
Van der, B.P.; Traversari, C.; Chomez, P.; Lurquin, C.; de, P.E.; van den Eynde, B.J.; Knuth, A.; Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. J. Immunol. 2007, 178, 2617–2621.
[8]
Burkett, M.W.; Shafer-Weaver, K.A.; Strobl, S.; Baseler, M.; Malyguine, A. A novel flow cytometric assay for evaluating cell-mediated cytotoxicity. J. Immunother. 2005, 28, 396–402, doi:10.1097/01.cji.0000165357.11548.6d.
Clemente, C.G.; Mihm, M.C.; Bufalino, R.; Zurrida, S.; Collini, P.; Cascinelli, N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77, 1303–1310, doi:10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5.
[11]
Mihm, M.C., Jr.; Clemente, C.G.; Cascinelli, N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response. Lab. Invest. 1996, 74, 43–47.
[12]
Rivoltini, L.; Carrabba, M.; Huber, V.; Castelli, C.; Novellino, L.; Dalerba, P.; Mortarini, R.; Arancia, G.; Anichini, A.; Fais, S.; et al. Immunity to cancer: Attack and escape in T lymphocyte-tumor cell interaction. Immunol. Rev. 2002, 188, 97–113, doi:10.1034/j.1600-065X.2002.18809.x.
[13]
Keane, M.M.; Ettenberg, S.A.; Lowrey, G.A.; Russell, E.K.; Lipkowitz, S. Fas expression and function in normal and malignant breast cell lines. Cancer Res. 1996, 56, 4791–4798.
[14]
Evavold, B.D.; Sloan-Lancaster, J.; Allen, P.M. Tickling the TCR: Selective T cell functions stimulated by altered peptide ligands. Immunol. Today 1993, 14, 602–609, doi:10.1016/0167-5699(93)90200-5.
[15]
Sloan-Lancaster, J.; Allen, P.M. Altered peptide ligand-induced partial T cell activation: Molecularmechanisms and role in T cell biology. Annu. Rev. Immunol. 1996, 14, 1–27, doi:10.1146/annurev.immunol.14.1.1.
[16]
Wang, T.; Niu, G.; Kortylewski, M.; Burdelya, L.; Shain, K.; Zhang, S.; Bhattacharya, R.; Gabrilovich, D.; Heller, R.; Coppola, D.; et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 2004, 10, 48–54, doi:10.1038/nm976.
[17]
Charles, G.; Elizabeth Jaffee, D.; Pardoll, D.M. Mechanisms of immune evasion by tumors. Adv. Immunol. 2006, 90, 51–81, doi:10.1016/S0065-2776(06)90002-9.
[18]
Cabrera, T.; Collado, A.; Fernandez, M.A.; Ferron, A.; Sancho, J.; Ruiz-Cabello, F.; Garrido, F. High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens 1998, 52, 114–123, doi:10.1111/j.1399-0039.1998.tb02274.x.
[19]
Zaremba, S.; Barzaga, E.; Zhu, M.; Soares, N.; Tsang, K.Y.; Schlom, J. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 1997, 57, 4570–4577.
Yamaguchi, S.; Tatsumi, T.; Takehara, T.; Sasakawa, A.; Yamamoto, M.; Kohga, K.; Miyagi, T.; Kanto, T.; Hiramastu, N.; Akagi, T.; et al. EphA2-Derived peptide vaccine with amphiphilic poly(gamma-glutamic acid) nanoparticles elicits an anti-tumor effect against mouse liver tumor. Cancer Immunol. Immunother. 2010, 59, 759–767, doi:10.1007/s00262-009-0796-2.
[22]
Wang, R.F. Human tumor antigens: Implications for cancer vaccine development. J. Mol. Med. 1999, 77, 640–655, doi:10.1007/s001099900042.
[23]
Shafer-Weaver, K.A.; Sayers, T.; Kuhns, D.B.; Strobl, S.L.; Burkett, M.W.; Baseler, M.; Malyguine, A. Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay. J. Transl. Med. 2004, 2, 31, doi:10.1186/1479-5876-2-31.
[24]
Umansky, V.; Malyguine, A.; Shurin, M. New perspectives in cancer immunotherapy and immunomonitoring. Future Oncol. 2009, 5, 941–944, doi:10.2217/fon.09.62.
[25]
He, L.; Hakimi, J.; Salha, D.; Miron, I.; Dunn, P.; Radvanyi, L. A sensitive flow cytometry-based cytotoxic T-lymphocyte assay through detection of cleaved caspase 3 in target cells. J. Immunol. Methods 2005, 304, 43–59, doi:10.1016/j.jim.2005.06.005.
[26]
Xu, Y.; Theobald, V.; Sung, C.; DePalma, K.; Atwater, L.; Seiger, K.; Perricone, M.A.; Richards, S.M. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients. J. Transl. Med. 2008, 6, 61, doi:10.1186/1479-5876-6-61.
[27]
Rappu, P.; Nylund, C.; Ristiniemi, N.; Kulpakko, J.; Vihinen, P.; Hernberg, M.; Mirtti, T.; Alanen, K.; Kallajoki, M.; Vuoristo, M.S.; et al. Detection of melanoma-derived cancer-testis antigen CT16 in patient sera by a novel immunoassay. Int. J. Cancer 2011, 128, 2382–2392.
[28]
Goydos, J.S.; Elder, E.; Whiteside, T.L.; Finn, O.J.; Lotze, M.T. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 1996, 63, 298–304, doi:10.1006/jsre.1996.0264.
[29]
Tsuruma, T.; Hata, F.; Torigoe, T.; Furuhatal, T.; Idenoue, S.; Kurotaki, T.; Yamamoto, M.; Yagihashi, A.; Ohmura, T.; Yamaguchi, K.; et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J. Transl. Med. 2004, 2, 19, doi:10.1186/1479-5876-2-19.
[30]
Karanikas, V.; Colau, D.; Baurain, J.F.; Chiari, R.; Thonnard, J.; Gutierrez-Roelens, I.; Goffinet, C.; van Schaftingen, E.V.; Weynants, P.; Boon, T.; et al. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res. 2001, 61, 3718–3724.
[31]
Yoshimatsu, K.; Yokomizo, H.; Osawa, G.; Fujimoto, T.; Otani, T.; Tsunoda, T.; Nakamura, Y.; Ogawa, K. Phase I study of combination therapy with peptide vaccine and anti-cancer drug for colorectal cancer. Gan To Kagaku Ryoho 2008, 35, 2268–2270.
[32]
Begley, J.; Vo, D.D.; Morris, L.F.; Bruhn, K.W.; Prins, R.M.; Mok, S.; Koya, R.C.; Garban, H.J.; Comin-Anduix, B.; Craft, N.; et al. Immunosensitization with a Bcl-2 small molecule inhibitor. Cancer Immunol. Immunother. 2009, 58, 699–708, doi:10.1007/s00262-008-0592-4.
[33]
Kaumaya, P.T.; Foy, K.C.; Garrett, J.; Rawale, S.V.; Vicari, D.; Thurmond, J.M.; Lamb, T.; Mani, A.; Kane, Y.; Balint, C.R.; et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J. Clin. Oncol. 2009, 27, 5270–5277, doi:10.1200/JCO.2009.22.3883.
[34]
Tan, G.H.; Li, Y.N.; Huang, F.Y.; Wang, H.; Bai, R.Z.; Jang, J. Combination of recombinant xenogeneic endoglin DNA and protein vaccination enhances anti-tumor effects. Immunol. Invest 2007, 36, 423–440, doi:10.1080/08820130701361103.
[35]
Saha, A.; Chatterjee, S.K.; Foon, K.A.; Celis, E.; Bhattacharya-Chatterjee, M. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Cancer Res. 2007, 67, 2881–2892, doi:10.1158/0008-5472.CAN-06-3045.
[36]
Mukherjee, P.; Pathangey, L.B.; Bradley, J.B.; Tinder, T.L.; Basu, G.D.; Akporiaye, E.T.; Gendler, S.J. MUC1-Specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model. Vaccine 2007, 25, 1607–1618.
[37]
Ali, S.A.; Ahmad, M.; Lynam, J.; McLean, C.S.; Entwisle, C.; Loudon, P.; Choolun, E.; McArdle, S.E.B.; Li, G.; Mian, S.; et al. Anti-Tumour therapeutic efficacy of OX40L in murine tumour model. Vaccine 2004, 22, 3585–3594, doi:10.1016/j.vaccine.2004.03.041.
[38]
Mazzaferro, V.; Coppa, J.; Carrabba, M.G.; Rivoltini, L.; Schiavo, M.; Regalia, E.; Mariani, L.; Camerini, T.; Marchianò, A.; Andreola, S.; et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res. 2003, 9, 3235–3245.
[39]
Miyagi, Y.; Imai, N.; Sasatomi, T.; Yamada, A.; Mine, T.; Katagiri, K.; Nakagawa, M.; Muto, A.; Okouchi, S.; Isomoto, H.; et al. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin. Cancer Res. 2001, 7, 3950–3962.
[40]
Imai, N.; Harashima, N.; Ito, M.; Miyagi, Y.; Harada, M.; Yamada, A.; Itoh, K. Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases. Int. J. Cancer 2001, 94, 237–242, doi:10.1002/ijc.1461.
[41]
Fong, L.; Hou, Y.; Rivas, A.; Benike, C.; Yuen, A.; Fisher, G.A.; Davis, M.M.; Engleman, E.G. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 2001, 98, 8809–8814.
[42]
Oba, S.M.; Wang, Y.J.; Song, J.P.; Li, Z.Y.; Kobayashi, K.; Tsugane, S.; Hamada, G.S.; Tanaka, M.; Sugimura, H. Genomic structure and loss of heterozygosity of EPHB2 in colorectal cancer. Cancer Lett. 2001, 164, 97–104, doi:10.1016/S0304-3835(00)00716-3.
[43]
Cheng, N.; Brantley, D.M.; Chen, J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev. 2002, 13, 75–85, doi:10.1016/S1359-6101(01)00031-4.
[44]
Saito, T.; Masuda, N.; Miyazaki, T.; Kanoh, K.; Suzuki, H.; Shimura, T.; Asao, T.; Kuwano, H. Expression of EphA2 and E-cadherin in colorectal cancer: Correlation with cancer metastasis. Oncol. Rep. 2004, 11, 605–611.
[45]
Yamaguchi, S.; Tatsumi, T.; Takehara, T.; Sakamori, R.; Uemura, A.; Mizushima, T.; Ohkawa, K.; Storkus, W.J.; Hayashi, N. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer 2007, 110, 1469–1477, doi:10.1002/cncr.22958.
[46]
Altieri, D.C. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. 2001, 7, 542–547, doi:10.1016/S1471-4914(01)02243-2.
[47]
Kawasaki, H.; Altieri, D.C.; Lu, C.D.; Toyoda, M.; Tenjo, T.; Tanigawa, N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998, 58, 5071–5074.
[48]
Hirohashi, Y.; Torigoe, T.; Maeda, A.; Nabeta, Y.; Kamiguchi, K.; Sato, T.; Yoda, J.; Ikeda, H.; Hirata, K.; Yamanaka, N.; et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin. Cancer Res. 2002, 8, 1731–1739.
[49]
Idenoue, S.; Hirohashi, Y.; Torigoe, T.; Sato, Y.; Tamura, Y.; Hariu, H.; Yamamoto, M.; Kurotaki, T.; Tsuruma, T.; Asanuma, H.; et al. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin. Cancer Res. 2005, 11, 1474–1482.
[50]
Tsuruma, T.; Iwayama, Y.; Ohmura, T.; Katsuramaki, T.; Hata, F.; Furuhata, T.; Yamaguchi, K.; Kimura, Y.; Torigoe, T.; Toyota, N.; et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J. Transl. Med. 2008, 6, 24, doi:10.1186/1479-5876-6-24.
[51]
Sasatomi, T.; Suefuji, Y.; Matsunaga, K.; Yamana, H.; Miyagi, Y.; Araki, Y.; Ogata, Y.; Itoh, K.; Shirouzu, K. Expression of tumor rejection antigens in colorectal carcinomas. Cancer 2002, 94, 1636–1641, doi:10.1002/cncr.10421.
[52]
Miyagi, Y.; Imai, N.; Sasatomi, T.; Yamada, A.; Mine, T.; Katagiri, K.; Nakagawa, M.; Muto, A.; Okouchi, S.; Isomoto, H.; et al. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin. Cancer Res. 2001, 7, 3950–3962.
[53]
Miyamoto, S.; Nakamura, M.; Shitara, K.; Nakamura, K.; Ohki, Y.; Ishii, G.; Goya, M.; Kodama, K.; Sangai, T.; Maeda, H.; et al. Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers. Clin. Cancer Res. 2005, 11, 3494–3502.
[54]
Saha, A.; Chatterjee, S.K.; Foon, K.A.; Celis, E.; Bhattacharya-Chatterjee, M. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Cancer Res. 2007, 67, 2881–2892, doi:10.1158/0008-5472.CAN-06-3045.
[55]
Niv, Y. MUC1 and colorectal cancer pathophysiology considerations. World J. Gastroenterol. 2008, 14, 2139–2141, doi:10.3748/wjg.14.2139.
